Australia markets closed

InnoCan Pharma Corp (IP4.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.2140+0.0050 (+2.39%)
At close: 08:22PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
Total revenue
1,440
2,559
196
8
Cost of revenue
919
452
75
5
Gross profit
521
2,107
121
3
Operating expenses
Research development
1,480
1,526
1,399
1,744
Selling general and administrative
6,171
6,847
6,202
2,984
Total operating expenses
7,651
8,373
7,601
4,728
Operating income or loss
-7,130
-6,266
-7,480
-4,725
Interest expense
4
2
13
8
Total other income/expenses net
3,806
2,359
-2,598
-5,220
Income before tax
-3,324
-3,888
-10,091
-9,953
Income tax expense
0
1
0
0
Income from continuing operations
-3,324
-3,889
-10,091
-9,953
Net income
-3,129
-3,764
-10,047
-9,953
Net income available to common shareholders
-3,129
-3,764
-10,047
-9,953
Basic EPS
-0.02
-0.02
-0.05
-0.06
Diluted EPS
-0.02
-0.02
-0.05
-0.06
Basic average shares
252,653
248,953
224,542
162,022
Diluted average shares
252,653
248,953
224,542
162,022